Patent · US Active

Chimeric antigen receptor specific for tumor cells

US12161705B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

MILTENYI BIOTEC B.V. & CO. KG · DE

Inventors

Dominik Eckardt · Moitzfeld, DE
Andreas Bosio · Cologne, DE
Jutta Kollet · Bonn, DE
Olaf Hardt · Cologne, DE
Andrzej Dzionek · Overath, DE
Stefan Tomiuk · Neunburg vorm Wald, DE

Key dates

Filing date	Mar 30, 2020
Grant date	Dec 10, 2024
Priority date	—
Expiry date	Nov 19, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.